Page 7 - Interim Analysis News Today

Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA (Vascular InterVentional Advances) Annual Conference have been announced. Leading physicians and researchers will present results from 21 clinical trials, from Monday, October 31, to Wednesday, November 2, at Wynn Las Vegas.

An interim safety analysis from ECZTEND, an open-label, 5-year extension trial, demonstrated consistent safety from the parent trials for up to 3.5 years of Adbry (tralokinumab-ldrm) treatment in

Pivotal results for efficacy and safety of Cosentyx (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology

/PRNewswire/ -- Leading physicians and researchers will present results from 21 clinical trials from Monday, October 31, to Wednesday, November 2, at the...

Analyses highlight long-term efficacy and safety results, including real-world data, from studies of SKYRIZI® (risankizumab) in moderate to severe...

 Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment  IDSMC Did Not Identify Any Safety ConcernsPhase 2 Study Target Enrollment Achieved; Final Data and Communication Expected in October 2023Conference Call and Webcast Today at 2:00 p.m. PDT/5:00 p.m. EDTSOUTH...

Insomnia is linked with anxiety and depression, and a clinical trial evaluates the impact of Somryst on these comorbidities.

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking...

Helix BioPharma Corp announced the appointment of Artur Gabor as the companys new permanent CEO, effective immediately. The clinical-stage...